Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $61.4 million.

  • Pliant Therapeutics' Shares Outstanding (Weighted Average) rose 111.23% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year increase of 111.23%. This contributed to the annual value of $60.5 million for FY2024, which is 309.87% up from last year.
  • Pliant Therapeutics' Shares Outstanding (Weighted Average) amounted to $61.4 million in Q3 2025, which was up 111.23% from $61.4 million recorded in Q2 2025.
  • Pliant Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $61.4 million during Q3 2025, with a 5-year trough of $35.6 million in Q1 2021.
  • For the 5-year period, Pliant Therapeutics' Shares Outstanding (Weighted Average) averaged around $50.7 million, with its median value being $58.7 million (2023).
  • As far as peak fluctuations go, Pliant Therapeutics' Shares Outstanding (Weighted Average) surged by 177836.79% in 2021, and later surged by 111.23% in 2025.
  • Over the past 5 years, Pliant Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $35.8 million in 2021, then rose by 17.21% to $42.0 million in 2022, then skyrocketed by 39.75% to $58.7 million in 2023, then increased by 3.1% to $60.5 million in 2024, then grew by 1.43% to $61.4 million in 2025.
  • Its last three reported values are $61.4 million in Q3 2025, $61.4 million for Q2 2025, and $61.2 million during Q1 2025.